Equillium, Inc. (EQ): Price and Financial Metrics

Equillium, Inc. (EQ): $0.69

0.03 (-3.71%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add EQ to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#22 of 348

in industry

EQ Price/Volume Stats

Current price $0.69 52-week high $3.25
Prev. close $0.72 52-week low $0.45
Day low $0.69 Volume 102,800
Day high $0.73 Avg. volume 363,515
50-day MA $1.45 Dividend yield N/A
200-day MA $1.22 Market Cap 24.33M

EQ Stock Price Chart Interactive Chart >


Equillium, Inc. (EQ) Company Bio


Equillium Inc. is leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is based in La Jolla, California.


EQ Latest News Stream


Event/Time News Detail
Loading, please wait...

EQ Latest Social Stream


Loading social stream, please wait...

View Full EQ Social Stream

Latest EQ News From Around the Web

Below are the latest news stories about EQUILLIUM INC that investors may wish to consider to help them evaluate EQ as an investment opportunity.

EQ Bank Card launches in Québec as Carte Banque EQ

EQ Bank (Banque EQ in Québec) is offering Québec customers a new way to earn, save and spend their money, with the introduction of its popular EQ Bank Card1 (Carte Banque EQ). Customers can use the card to withdraw cash for free at any ATM in the country, earn cash back on their spending, earn high interest on their card balance, and travel without paying foreign currency conversion fees.

Yahoo | November 20, 2023

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

LA JOLLA, Calif., November 13, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study evaluating itolizumab in lupus nephritis patients was presented at ACR Convergence, the annual meeting of the American College of Rheumatology (ACR). The data presented by Dr. Kenneth Kalunian, Professor, Medicine, UCSD School

Yahoo | November 13, 2023

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif., November 08, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates.

Yahoo | November 8, 2023

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

LA JOLLA, Calif., November 06, 2023--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that data from the Type B portion of the EQUALISE study in lupus nephritis patients was presented at the annual meeting of the American Society of Nephrology (ASN). The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine

Yahoo | November 6, 2023

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

Yahoo | October 24, 2023

Read More 'EQ' Stories Here

EQ Price Returns

1-mo -54.30%
3-mo -75.53%
6-mo 5.02%
1-year -11.48%
3-year -88.42%
5-year -88.50%
YTD -4.56%
2023 -31.79%
2022 -71.88%
2021 -29.53%
2020 58.28%
2019 -58.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!